Sign in
PKBOW Stock Price, Chart, Stats & News
Peak Bio, Inc.
Save
Peak Bio, Inc. (PKBOW) does not currently pay a dividend.
531,873
Market cap
–
Current P/E
–
Forward P/E
PKBOW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | 30420.43% |
ROE | -24.59% |
D/E | – |
Interest coverage ratio | -1.11x |
PKBOW valuation
P/E | – |
P/S | – |
P/B | 0.35x |
P/CF | -0.00x |
P/FCF | -0.22x |
P/OCF | -0.00x |
PEG | 0.00x |
EV multiple | 0.17x |
About
Peak Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for significant unmet medical requirements within the fields of oncology and inflammation. The company leverages its proprietary toxin, PH-1 (also referred to as Thailanstatin), a spliceosome modulator, to engineer its initial suite of innovative Antibody-Drug Conjugate (ADC) product candidates, specifically aimed at addressing critical gaps for cancer patients. Its foremost experimental therapy, PHP-303, a small molecule, is poised to enter a Phase II dose clinical study for the rare genetic condition, Alpha1 anti-trypsin deficiency (AATD).
Similar securities
Based on sector and market capitalization
Report issue